A subsidiary of Air Liquide Healthcare, Seppic is opening a new laboratory dedicated to fermentation biotechnologies at the Air Liquide Group's Delaware Innovation Campus.
Historically used to produce and preserve foodstuffs, the fermentation process offers many advantages for the cosmetics and health industries. This technology makes it possible to manufacture bio-based ingredients while minimizing their impact on the environment and biodiversity, and controlling land use.
Seppic, which designs, produces and distributes a wide range of specialty ingredients, has just opened a dedicated laboratory in the United States, within the Air Liquide Group's Delaware Innovation Campus. The stated aim: to develop new ingredients combining efficacité and a response to societal challenges in the fields of cosmetics and health, in line with the company's approach to committed innovation.
This choice of location within the Delaware Innovation Campus will enable Seppic to benefit from strong synergies with Air Liquide's other R&D activities on the Campus, where Seppic's American customer service technical center has already been present since 2007, as well as with the very dynamic American research ecosystem in the biotechnology field. This opening in the United States is a significative step in Seppic's strategy of internationalizing its research & innovation.
"Following the opening in 2024 of new Research facilities at our Castres site in France, Seppic continues to invest for the future with this laboratory in the United States. It will enable us to continue innovating for the performance of our ingredients by addressing the needs of our markets".says Managing Director Hannes Moeller.
